Literature DB >> 23159101

Carotid intima-media thickness in patients with subclinical hypothyroidism: a meta-analysis.

Ning Gao1, Wei Zhang, Yu-zhen Zhang, Qing Yang, Shao-hua Chen.   

Abstract

OBJECTIVE: Subclinical hypothyroidism (SCH) has been associated with increased carotid intima-media thickness (IMT) in recent studies, but this relationship is controversial. The aim of this study was to assess whether carotid IMT in patients with SCH differs from that in euthyroid subjects.
METHODS: Prior to November 2011, we searched PUBMED, EMBASE, COCHRANE LIBRARY databases and the bibliographies of key articles to identify studies that reported carotid IMT in patients with SCH compared with euthyroid subjects. Two reviewers independently evaluated each potential study for eligibility, assessed the methodological quality, and extracted the data.
RESULTS: We identified 8 observational studies with 3602 patients that met the eligibility criteria. In patients with SCH, the pooled estimate of the weighted mean difference (WMD) of increased carotid IMT was 0.056 mm (95% CI 0.020, 0.092; P = 0.002). Sensitivity analysis using a pooled sample of the 7 higher-quality studies demonstrated higher carotid IMT level in patients with SCH compared with those with euthyroidism (WMD, 0.064 mm, 95% CI 0.024, 0.105; P = 0.002). In a subgroup analysis, SCH was also associated with a significant increase in carotid IMT among patients with a mean TSH > 10.0 mIU/l (WMD, 0.082 mm, 95% CI 0.049, 0.116; P = 0.00). SCH was associated with a significant increase in systolic blood pressure (SBP), triglyceride (TG) levels, total cholesterol (TC) levels, low-density lipoprotein (LDL) levels and with a decrease in fasting plasma glucose (FPG).
CONCLUSION: This meta-analysis indicates that SCH is associated with an increased carotid IMT, which may due to elevated thyrotropin (TSH), dyslipidemia and hypertension. Increased IMT can also be present in patients with serum TSH values less than 10 mIU/l, although there is significant heterogeneity. Prospective studies with larger samples are necessary to evaluate these observations.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23159101     DOI: 10.1016/j.atherosclerosis.2012.10.070

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  38 in total

Review 1.  Subclinical hypothyroidism in childhood - current knowledge and open issues.

Authors:  Mariacarolina Salerno; Donatella Capalbo; Manuela Cerbone; Filippo De Luca
Journal:  Nat Rev Endocrinol       Date:  2016-07-01       Impact factor: 43.330

2.  Long non-coding RNA NEAT1 regulates endothelial functions in subclinical hypothyroidism through miR-126/TRAF7 pathway.

Authors:  Li Wang; Jingzhi Liu; Kunna Lu; Yuyu Qiu; Xiaoxia Li; Feng Yue; Xinhuan Zhang
Journal:  Hum Cell       Date:  2021-03-07       Impact factor: 4.174

3.  Meta-analytic evidence for increased low-grade systemic inflammation and oxidative stress in hypothyroid patients. Can levothyroxine replacement therapy mitigate the burden?

Authors:  Mariana L Tellechea
Journal:  Endocrine       Date:  2020-09-02       Impact factor: 3.633

4.  Thyroid Function and High-Sensitivity C-Reactive Protein in Cross-Sectional Results from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil): Effect of Adiposity and Insulin Resistance.

Authors:  Érique José F Peixoto de Miranda; Márcio Sommer Bittencourt; Itamar S Santos; Paulo A Lotufo; Isabela M Benseñor
Journal:  Eur Thyroid J       Date:  2016-09-02

5.  TSHB mRNA is linked to cholesterol metabolism in adipose tissue.

Authors:  José María Moreno-Navarrete; María Moreno; Francisco Ortega; Gemma Xifra; Shangyu Hong; John M Asara; José C E Serrano; Mariona Jové; Pavlos Pissios; Matthias Blüher; Wifredo Ricart; Manuel Portero-Otin; José Manuel Fernández-Real
Journal:  FASEB J       Date:  2017-06-23       Impact factor: 5.191

6.  Menopause modulates the association between thyrotropin levels and lipid parameters: The SardiNIA study.

Authors:  Alessandro P Delitala; Maristella Steri; Maria Grazia Pilia; Mariano Dei; Sandra Lai; Giuseppe Delitala; David Schlessinger; Francesco Cucca
Journal:  Maturitas       Date:  2016-07-14       Impact factor: 4.342

7.  Low-normal free thyroxine confers decreased serum bilirubin in type 2 diabetes mellitus.

Authors:  Petronella E Deetman; Arjan J Kwakernaak; Stephan J L Bakker; Robin P F Dullaart
Journal:  Thyroid       Date:  2013-09-04       Impact factor: 6.568

Review 8.  Subclinical Hypothyroidism and the Risk of Stroke Events and Fatal Stroke: An Individual Participant Data Analysis.

Authors:  Layal Chaker; Christine Baumgartner; Wendy P J den Elzen; M Arfan Ikram; Manuel R Blum; Tinh-Hai Collet; Stephan J L Bakker; Abbas Dehghan; Christiane Drechsler; Robert N Luben; Albert Hofman; Marileen L P Portegies; Marco Medici; Giorgio Iervasi; David J Stott; Ian Ford; Alexandra Bremner; Christoph Wanner; Luigi Ferrucci; Anne B Newman; Robin P Dullaart; José A Sgarbi; Graziano Ceresini; Rui M B Maciel; Rudi G Westendorp; J Wouter Jukema; Misa Imaizumi; Jayne A Franklyn; Douglas C Bauer; John P Walsh; Salman Razvi; Kay-Tee Khaw; Anne R Cappola; Henry Völzke; Oscar H Franco; Jacobijn Gussekloo; Nicolas Rodondi; Robin P Peeters
Journal:  J Clin Endocrinol Metab       Date:  2015-04-09       Impact factor: 5.958

9.  Relationship of TSH Levels with Cardiometabolic Risk Factors in US Youth and Reference Percentiles for Thyroid Function.

Authors:  Xinlei Chen; Shuliang Deng; Cecilia Sena; Chuhan Zhou; Vidhu V Thaker
Journal:  J Clin Endocrinol Metab       Date:  2021-03-08       Impact factor: 5.958

10.  Thyroid function, reduced kidney function and incident chronic kidney disease in a community-based population: the Atherosclerosis Risk in Communities study.

Authors:  Ulla T Schultheiss; Natalie Daya; Morgan E Grams; Jochen Seufert; Michael Steffes; Josef Coresh; Elizabeth Selvin; Anna Köttgen
Journal:  Nephrol Dial Transplant       Date:  2017-11-01       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.